These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 34097922)

  • 1. Golimumab for the Treatment of Hidradenitis Suppurativa in Patients with Previous TNF-α Treatment Failure.
    Melendez-Gonzalez MDM; Hamad J; Sayed C
    J Invest Dermatol; 2021 Dec; 141(12):2975-2979. PubMed ID: 34097922
    [No Abstract]   [Full Text] [Related]  

  • 2. Successful treatment of recalcitrant gluteal hidradenitis suppurativa with brodalumab after anti-TNF failure.
    Arenbergerova M; Arenberger P; Marques E; Gkalpakiotis S
    Int J Dermatol; 2020 Jun; 59(6):733-735. PubMed ID: 32012238
    [No Abstract]   [Full Text] [Related]  

  • 3. Hidradenitis suppurativa management using tumor necrosis factor inhibitors in patients younger than 18 years: A series of 12 cases.
    Fougerousse AC; Reguiai Z; Roussel A; Bécherel PA;
    J Am Acad Dermatol; 2020 Jul; 83(1):199-201. PubMed ID: 32151626
    [No Abstract]   [Full Text] [Related]  

  • 4. Hidradenitis suppurativa managed with adalimumab.
    Yamauchi PS; Mau N
    J Drugs Dermatol; 2009 Feb; 8(2):181-3. PubMed ID: 19213236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world experience of adalimumab in the treatment of hidradenitis suppurativa.
    Khosravi H; Anderson AM; Kettering C; Mizes A; Patton T
    J Am Acad Dermatol; 2021 May; 84(5):1406-1409. PubMed ID: 33316329
    [No Abstract]   [Full Text] [Related]  

  • 6. Summaries for patients. Adalimumab for the treatment of hidradenitis suppurativa.
    Ann Intern Med; 2012 Dec; 157(12):I-50. PubMed ID: 23247950
    [No Abstract]   [Full Text] [Related]  

  • 7. Ultrasonographic railway sign in tunnels as a new independent risk factor of adalimumab failure in hidradenitis suppurativa.
    Krajewski PK; Jfri A; Ochando-Ibernón G; Martorell A
    J Am Acad Dermatol; 2023 Mar; 88(3):732-734. PubMed ID: 36206936
    [No Abstract]   [Full Text] [Related]  

  • 8. Paradoxical Hidradenitis Suppurativa in Patients Receiving TNF-α Inhibitors: Case Series, Systematic Review, and Case Meta-Analysis.
    Salvador-Rodriguez L; Montero-Vílchez T; Arias-Santiago S; Molina-Leyva A
    Dermatology; 2020; 236(4):307-313. PubMed ID: 32135533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adalimumab Induces a Wound Healing Profile in Patients with Hidradenitis Suppurativa by Regulating Macrophage Differentiation and Matrix Metalloproteinase Expression.
    Cao Y; Harvey BP; Hong F; Ruzek M; Wang J; Murphy ER; Kaymakcalan Z
    J Invest Dermatol; 2021 Nov; 141(11):2730-2740.e9. PubMed ID: 33965402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-tumor necrosis factor (TNF)-induced lupus in a patient with hidradenitis suppurativa.
    Turk D; Vellaichamy G; Lyons AB; Parks-Miller A; Nelson T; Meysami A; Hamzavi IH
    Int J Dermatol; 2020 Mar; 59(3):e73-e74. PubMed ID: 31633193
    [No Abstract]   [Full Text] [Related]  

  • 11. Effective long-term control of refractory hidradenitis suppurativa with adalimumab after failure of conventional therapy.
    Arenbergerova M; Gkalpakiotis S; Arenberger P
    Int J Dermatol; 2010 Dec; 49(12):1445-9. PubMed ID: 21091684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of severe recalcitrant hidradenitis suppurativa with adalimumab.
    Harde V; Mrowietz U
    J Dtsch Dermatol Ges; 2009 Feb; 7(2):139-41. PubMed ID: 19371236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term adalimumab treatment of hidradenitis suppurativa: Results and practical insights from a real-life experience.
    Bettoli V; Manfredini M; Calamo G; Forconi R; Bencivelli D; Mantovani L; Pellacani G; Corazza M
    Dermatol Ther; 2018 Nov; 31(6):e12737. PubMed ID: 30295378
    [No Abstract]   [Full Text] [Related]  

  • 14. Impact of Treatment With TNF-α Inhibitors for Hidradenitis Suppurativa During the COVID-19 Pandemic.
    Benesh G; Andriano TM; Babbush KM; Hosgood HD; Cohen SR
    J Cutan Med Surg; 2021; 25(4):446-448. PubMed ID: 33625899
    [No Abstract]   [Full Text] [Related]  

  • 15. MABp1 Targeting IL-1α for Moderate to Severe Hidradenitis Suppurativa Not Eligible for Adalimumab: A Randomized Study.
    Kanni T; Argyropoulou M; Spyridopoulos T; Pistiki A; Stecher M; Dinarello CA; Simard J; Giamarellos-Bourboulis EJ
    J Invest Dermatol; 2018 Apr; 138(4):795-801. PubMed ID: 29129600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-savings of adalimumab in hidradenitis suppurativa: a retrospective analysis of a real-world cohort.
    Argyropoulou M; Kanni T; Kyprianou M; Melachroinopoulos N; Giamarellos-Bourboulis EJ
    Br J Dermatol; 2019 May; 180(5):1161-1168. PubMed ID: 30192377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of Characteristics and Trends in Treatment Response of Hidradenitis Suppurativa Patients: A Southern US Cohort Study.
    Peterson GC; Preston A; Frieder J; Wang X; Paek SY
    Dermatology; 2020; 236(5):413-420. PubMed ID: 31935718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hidradenitis suppurativa with perifolliculitis capitis abscedens et suffodiens successfully treated with a human anti-tumour necrosis factor monoclonal antibody.
    Minakawa S; Matsuzaki Y; Rokunohe D; Kumagai N; Kurose A; Kushibiki M; Kayaba H; Sawamura D
    Clin Exp Dermatol; 2021 Dec; 46(8):1586-1588. PubMed ID: 34096639
    [No Abstract]   [Full Text] [Related]  

  • 19. Golimumab, as an alternative treatment in patients with coexisting hidradenitis suppurativa and arthritis after adalimumab failure: Report of two cases.
    Ramos FJM; Ruiz RG; Puchades AM
    Dermatol Ther; 2022 Mar; 35(3):e15266. PubMed ID: 34913547
    [No Abstract]   [Full Text] [Related]  

  • 20. Metabolic, pharmacokinetic, and toxicological issues of biologic therapies currently used in the treatment of hidradenitis suppurativa.
    Molinelli E; Sapigni C; Campanati A; Brisigotti V; Offidani A
    Expert Opin Drug Metab Toxicol; 2020 Nov; 16(11):1019-1037. PubMed ID: 32896186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.